| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
Human artificial chromosome vector (HAC) is promising for the development of gene- and cell-therapy for Duchenne muscular dystrophy, which is a genetic disorder with an X-linked recessive inheritance pattern . However, HAC should be developed and introduced to target cells in a condition without animal cells. In this study, we developed a chromosome modification technology for human chromosome in CHO or A9 cells of the model cells of somatic cells with CRISPR/Cas9, called genome editing tool. On the other hand, the chromosome modification technology in human cells was examined and chemical compounds was screened towards the development of microcell-mediated chromosome transferring with human cells as a donor of a chromosome. Although these studies did not showed an expected results, further consideration should be required towards the achievements of the development of these technologies.
|
